Inquiry Basket
Synthetic oligonucleotides serve as the molecular recognition reagents for diagnostic nucleic acid tests. Errors associated with primers and probes are a major reason why nucleic acid tests fail. Poor primer design results in non-specific background that can hide the detection of the target. Degraded probes or poor manufacturing quality controls can cause variations in assay performance. In addition, because diagnostic tests are often designed to detect very low amounts of a pathogen's nucleic acid, they are especially sensitive to contamination. Small amounts of nucleic acid contaminants such as carryover from previously amplified DNA or leftover DNA from fungus growth in reagents can lead to false positive results on a no-template control reaction.
Working principle of polymerase chain reaction.1,5
Synthetic oligonucleotides are used as the recognition elements in molecular diagnostic assays. These oligonucleotides can be designed to detect unique sequences in the nucleic acid from a virus or disease state. Oligonucleotides can be used as primers to begin replication of a target sequence or they can be labeled and used as probes to detect a sequence of interest. The sequence composition of these oligonucleotides is critical for successful diagnostics. The wrong sequence can cause problems with failed PCR reactions or false positives/negatives. Oligonucleotides can also be used for assay controls and calibration. They are important for creating a standard curve for determining an unknown sample's concentration. Because of this, quality of the oligonucleotides goes hand in hand with the quality of the overall diagnostic assay.
| Oligonucleotide Type | Primary Function | Critical Quality Requirements |
| Amplification Primers | Initiate polymerase-mediated target exponential replication | Thermodynamic balance, minimal secondary structure, high specificity |
| Detection Probes | Generate specific fluorescent or colorimetric signals upon target recognition | Chemical stability of conjugated labels, resistance to nuclease degradation |
| Internal Controls | Monitor reaction inhibition and validate negative results | Non-competitive amplification, distinct detection signature from target |
| Positive Calibrators | Establish quantitative standards for copy number determination | Sequence fidelity, accurate concentration determination, traceability |
Table 1 Functional Roles of Oligonucleotide Components in Diagnostic Assays
Applications of oligonucleotides in clinical assays can often overlap. For example, probes used as primers will also have detectable sequence elements built in. Probes are often used as internal amplification controls to rule out false negatives due to reaction inhibitors. Positive calibrators will often contain sequence information that can be used as a probe. As you can see there are many applications where multiple types of oligonucleotides can be used in one reaction. This redundancy can minimize error but can also cause competition or quenching if not carefully optimized. Primer sequences are selected to bind to the template of interest with high specificity. In addition, the Tm of the primer should be appropriate for universal cycling conditions. It is also critical that primer sequences do not have homology with human genomic DNA. Probe sequences should be selected to hybridize specifically to the amplicon of interest and not to non-specific amplification products. This is especially important when using an intercalating dye for detection.
Clinical settings further limit their design and use by requiring higher standards than a researcher may utilize in the laboratory. Sample sources for assays are typically more difficult because they are complex mixtures that include polymerase inhibitors, nucleases, as well as mixed genetic backgrounds that could affect primer binding and probe-targeting. Assays must also be sensitive to detect even a single copy of a pathogen genome. These issues mean that if there is a decrease in primer efficiency or probe binding, the assay may become negative. A clinical assay also must be robust enough to return consistent results over a long period of time and between different operators. This makes them more susceptible to variability introduced from batch effects or degradation during storage. Lastly, clinical assays dictate patient care so issues such as primer-dimers or contamination introduced through poor oligonucleotide design can have severe consequences.
Poor oligonucleotide design is a leading cause of assay failure. Common problems with oligonucleotide design can lead to false positive results, decreased sensitivity and failure to amplify the target sequence in a clinical specimen. Structural problems are often due to poor sequence choice, which fails to target conserved sequence elements and allows for cross-reactivity with other related species or human DNA. In addition, poorly designed oligonucleotides with high or low GC content or significant melt-temperature asymmetry between the forward and reverse oligonucleotides can slow extension during PCR and hinder detection of low copy number sequences. Such false-negative and false-positive results have significant clinical implications when identifying pathogens.
Limited target specificity is when your oligonucleotide does not target a unique enough sequence in your clinical sample, thus allowing it to bind to other sites in the genome or even other species of bacteria. This occurs most often when you design primers based off of basic sequence alignment tools that do not take into account the thermodynamics of the melting temperatures involved. This allows for some seemingly mis-matched duplexes to anneal, creating pseudo products that make interpretation of your results challenging, especially when designing multiplex PCR reactions. Limitations in clinical specificity can occur if your primer binds to a site in the human genome that you are unaware of or if it binds to a similar region on a family of bacteria. This makes it impossible to know if you are getting a true positive signal for your target or not and often requires further validation.
Design flaws in oligo sequence — length, destabilizing factors such as secondary structure formation within the oligo, or unfavorable ends to the oligo — affect assay performance. Structures that allow for self-complementarity within a single oligo often lead to hairpin structures which hide the probe target from binding. Complementarity between primers can lead to primer-dimer formation, which causes a drain on resources for the actual desired reaction as well as artificial fluorescence during detection. Probe designs that are thermally unstable or have poorly chosen quenchers lead to higher background readings or slower reaction times. This is magnified in fast reactors as there is less time for inefficient oligos to bind to the template.
Cross-reactivity with non-target sequences is a concern with clinical molecular assays, especially those amplifying highly conserved genes from microorganisms or targeting families of viruses known to have significant sequence variation. Cross-reactivity may occur with sequences found in normal flora, the environment or even the human genome when there is sequence similarity to the target sequence, leading to false positive results. This can be troublesome with assays designed to detect RNA viruses as these pathogens may mutate rapidly. This means primer regions may be conserved enough to detect non-target strains and may not detect disease-causing strains. Testing against panels of related organisms as well as database screening with comprehensive databases including those of the human microbiome can help prevent this issue.
Diagnostic oligonucleotides produced chemically through stepwise phosphoramidite synthesis are imperfect, creating variability in clinical assays. Incorporation reactions do not go to completion and each cycle introduces a failure (short) product in addition to the desired full-length product. Deprotection/cleavage leaves protecting group byproducts that inhibit enzymatic reactions. All of these synthesis byproducts cause poor performance in clinical assays such as decreased amplification, higher background, or false positives. The effect is magnified when performing quantitative tests that rely on an exact known number of copies of the oligonucleotide participating in the reaction stoichiometrically. Single-base failures from nucleotide deletions and the other byproducts described above can compete with full-length oligonucleotides for target binding and/or incorporation by DNA polymerase. To prevent this from happening, it is necessary to purify the oligonucleotides after synthesis to select for full-length products.
Pros and cons of chemical automated synthesis and enzymatic synthesis of oligonucleotides.2,5
Stepwise chemical addition during solid phase synthesis is inefficient, leading to incomplete coupling reactions and truncated products that are missing a phosphate group on the 5' end of the oligonucleotide. In solution, truncated strands become part of the mixture that co-purifies with the desired product. These truncated strands are problematic when used as primers for PCR reactions. Because they have changed thermodynamic properties, truncated primers may bind to unintended sequences or may not act as efficient primers for extension by DNA polymerase. This can lead to variations in amplification efficiency as well as decreased specificity of the PCR reaction. If the truncated strand is part of the detection probe, this can lead to a failure to fluoresce when the target is bound.
Synthetic samples also contain small amounts of other chemicals such as leftover protecting group or organic residues used during synthesis, salts from the cleavage/deprotection reaction conditions, as well as product variants from DNA damage during chemical synthesis such as depurinated molecules or oxidized bases. These contaminants can interfere with clinical assays by reducing enzyme activity or changing salt concentration-dependent hybridization rates or by contributing to background signal that may mask true target signal. Sequence impurities can arise from random mutations, insertions or deletions of bases that occur in some fraction of the DNA sample. DNA sequence impurities will compete with the desired target for enzyme activity reducing amplification of the correct product. All of these issues make it important that only pure chemically complete DNA is used for clinical decision making.
| Synthesis Deficiency | Molecular Origin | Clinical Impact |
| Truncated Sequences | Incomplete phosphoramidite coupling during chain elongation | Altered binding affinity; non-specific amplification; failed probe detection |
| Chemical Impurities | Residual solvents, protecting groups, and synthesis byproducts | Polymerase inhibition; elevated background fluorescence; quantification errors |
| Sequence Heterogeneity | Depurination, oxidation, or nucleobase modifications | Competitive binding; reduced amplification efficiency; inconsistent standard curves |
| Degradation Artifacts | Acidic hydrolysis, oxidative damage during storage | Strand cleavage; declining assay sensitivity; temporal performance drift |
Table 2 Synthesis-Related Deficiencies and Their Diagnostic Consequences
Synthetic oligonucleotides are not chemically identical or consistent from lot to lot. The phosphoramidite approach to oligonucleotide synthesis proceeds iteratively and introduces truncated abort synthesis sequences, excess nucleotide protecting groups, and organic reagents that partition into the final product unless specifically separated. These species compete with the intact oligonucleotide for target binding and contribute background signal. The level of synthesis and purification needed to remove these species varies from batch to batch leading to inconsistent amounts of primer and background between batches affecting the Ct and standard curve values.
Oligonucleotides that have not been purified to homogeneity cause assay variability. Oligonucleotides that are shorter than the expected length may have different melting temperatures. These shortened oligonucleotides may nonspecifically anneal to other sequences or they may not act as substrates for DNA polymerase. Both of these situations reduce the efficiency of the reaction. Leftover nucleotide synthesis reagents and free nucleotides can interfere with the activity of the enzymes or affect salt-dependent binding of oligonucleotides. This results in fluctuations in the Ct value. Assays that use oligonucleotides that have not been purified enough will have higher CV%, internal control may not be amplified, and the standard curve may not be reproducible which prevents statistical analysis from being performed.
Batch-to-batch variation introduces bias into assays. Differences in coupling efficiencies of phosphoramidites used in synthesis, deprotection steps, or gel resolution lead to differences in the ratio of intact oligonucleotide to failed sequences. This affects the actual concentration of target sequence and can influence melting temperature, amplification efficiency, etc. Compare one lot of primers/probes to another and you will likely see variation in assay sensitivity. This can be an issue if you want to compare samples from different patients over time, or between sites in a clinical trial. Careful monitoring of the manufacturing process, extensive validation testing of every lot produced, and use of internal standards can help normalize between batches and over time.
Storage conditions are important for oligonucleotides. They are also chemically unstable in inappropriate storage conditions. Store oligonucleotides at ultralow temperatures for long-term storage. Store oligonucleotides at cool temperatures in buffered aqueous solutions for short-term storage. Oligonucleotides should be kept dry as water can promote acid hydrolysis and depurination. Oligonucleotides should be protected from nucleases that can cleave the oligonucleotide. The stability of oligonucleotides also depends on whether they are stored in a dried state or as a solution. As a general rule, dried oligonucleotides will have a longer shelf life at room temperature than liquid oligonucleotides.
Several degradation processes can cause oligonucleotides to become less effective. Acidic conditions or increased temperatures will cause oligonucleotides to cleave their phosphodiester backbone, creating shorter oligonucleotides that cannot be amplified or detected. Peroxidation can cause changes to the nucleobases such as pyrimidine dimers and modified purines, which can alter the structure of the DNA helix. Peroxidation can decrease the affinity of the oligonucleotide for its target and can make it more difficult for the polymerase to recognize the probe. Exposure to UV light can also affect oligonucleotides coupled to reporter groups. Reactive free radicals can cause breaks in the phosphodiester backbone as well as alter nucleobases. Degradation can occur over time if an oligonucleotide is not stored properly. As oligonucleotides degrade, they will affect the sensitivity of an assay by competing with the desired oligonucleotides for binding to enzymes.
Cycling freeze/thawing damages oligonucleotides primarily due to the mechanical stress of the process. Chemical stability is high, but solids that are excluded from the forming ice cause extremes of pH and ionic strength in small volumes, promoting acid catalyzed hydrolysis of the glycosidic bond. Phosphodiester bonds can be broken by shearing forces as ice crystals form, and free radicals can be generated upon thawing. Avoiding freeze/thawing by preparing aliquots of your material for one-time use is best. If aliquots must be exposed to room temperature, perform all manipulations quickly using a cold workstation and keep the sample frozen. Addition of EDTA to the buffer helps to prevent damage.
Diagnostic oligonucleotide production must meet the requirements for Medical Device Good Manufacturing Practices. This includes validation of quality management system (QMS) to ISO13485: 2016, which covers design control, process validation and change controls throughout manufacturing. Deviations from specifications require thorough investigations and corrective actions are validated to prevent recurrence. These regulatory standards require fully validated methods including analytical testing methods and finished product release, documented manufacturing process specifications, contamination controls, etc. Product manufacturers must also ensure they comply with Medical Device regulations for their regions, with technical dossier submittals that typically include analytical performance of the product, stability testing, and clinical validity.
Traceability requires documentation of all aspects of the manufacturing process from raw materials all the way to final product release. This includes recording lot numbers of starting materials such as nucleoside phosphoramidites, instrument maintenance records, laboratory environmental monitoring results and operator training records. Finished lots should be released only after they have been analyzed and a Certificate of Analysis (reporting identity, purity, concentration, and other results) is created confirming that the lot meets its specifications. Batch records should be retained for years after production to assist with any regulatory inspections or adverse event investigations. Traceability also includes Master Batch Records, standard operating procedures (SOPs), validation records, and other documentation necessary to reproduce a particular batch and be prepared for inspections. Traceability is required by regulations for components of in vitro diagnostic kits and can assure the laboratory about the quality of their reagents.
Facilities producing oligonucleotides intended for diagnostic applications must include procedures to avoid adventitious agents such as DNA or microbes from the environment contaminating the oligonucleotide batches or cross-contamination between batches. Areas where oligonucleotides are synthesized should be ISO Class 8 or better with airlocks, positive air pressure relative to adjacent spaces, and HEPA filtration of air to ensure low levels of bioburden. Operators of oligonucleotide synthesizers should follow gowning and segregation procedures, which keep oligonucleotide synthesis, purification, and liquid handling or dispensing in separate areas. Monitoring of the cleanroom environment (surface samples, viable particle monitoring, and air samples) ensures the areas remain free of adventitious agents.
Approaches to minimizing failures caused by oligonucleotides should be considered throughout oligonucleotide development, including design, synthesis and storage. Quality control during design includes ensuring that there is both no off-target hybridization and that the oligonucleotide will fold into the correct structure. In silico prediction is important, but wet lab testing must confirm that the oligonucleotide behaves as predicted. Additional care should be taken during the synthesis and purification of oligos to ensure quality. Oligonucleotides should be handled in a consistent manner, and storage temperatures should be monitored. Care should also be taken with storage of oligos to prevent failure of assays down the line. Finally, each batch of oligonucleotides should be tested before use to prevent failed experiments.
Best practices use algorithmic predictions that are then validated experimentally. Prediction programs are used to help weed out sequences likely to cause issues before any chemical synthesis even occurs. Various in silico programs that predict off target effects based on specificity, free energy, and structure are used during the design process. In addition using multiple databases to weed out possible targets that have cross reactivity helps. Purification methods depend on how rigorously the oligonucleotide will be used. If used for diagnostic purposes, oligonucleotides should be purified to homogeneity using HPLC or other chromatographic methods in order to remove shorter oligonucleotide by-products of synthesis and organic impurities. Desalting is not sufficient. Instead quality control should include verification of identity, purity, and concentration on a per-batch basis. In addition validation of functionality should be performed by comparing the performance of the oligonucleotide to a positive control. Testing should also be run with a no template control to ensure there is no contamination.
Temperature fluctuations, freeze/thaw cycles, and light exposure during storage and handling can affect oligonucleotide stability. Facilities should separate setup areas for reaction components and master mixes from areas used for sample preparation and analysis after PCR to prevent carryover of amplicons. Staff should gown appropriately and work from clean areas following good lab practices (RLP), including unidirectional traffic patterns, to avoid contaminating reaction mixtures with nucleases or microorganisms. Reaction components and samples should be protected from freeze/thaw cycles and excessive heat. Measures should be taken to prevent fluorescent dye degradation due to light exposure. Surfaces should be tested to ensure cleaning procedures have eliminated problematic compounds that could interfere with diagnostic test reactions.
| Preventive Layer | Key Measures | Intended Outcome |
| Design Optimization | Multi-algorithm specificity screening, secondary structure prediction, database homology analysis | Elimination of cross-reactivity and structural defects prior to synthesis |
| Purification Grading | Chromatographic separation, electrophoretic isolation, enzymatic contaminant removal | Removal of synthetic byproducts ensuring full-length product homogeneity |
| Quality Control | Batch-release testing, functional validation, concentration verification | Assurance of inter-batch consistency and performance reliability |
| Environmental Control | Zoned operations, unidirectional workflow, routine contamination monitoring | Prevention of carryover and adventitious contamination |
Table 3 Preventive Strategies for Oligonucleotide Integrity in Diagnostic Applications
Molecular diagnostic assays place significantly higher demands on oligonucleotide quality than routine research workflows. Even minor variations in sequence accuracy, purity, or batch consistency can affect sensitivity, specificity, and reproducibility—particularly in low-copy target detection. Our capabilities in diagnostic oligonucleotide synthesis include:
By aligning synthesis chemistry, purification control, and analytical validation with diagnostic performance requirements, oligonucleotide-related variability can be minimized.
If your molecular diagnostic assay exhibits inconsistent sensitivity, elevated background signal, unexpected false results, or variability between production batches, oligonucleotide design and quality may require review. A technical evaluation may be particularly valuable when working with:
Ensuring that primer and probe design parameters are aligned with appropriate synthesis and purification strategies can reduce performance variability and support long-term assay reliability. Contact our team to discuss your diagnostic oligonucleotide requirements and determine the most appropriate synthesis and quality strategy for your application.
References
